Endoscopic sleeve gastroplasty versus oral semaglutide for obesity: a real-world comparative cohort study
Endoscopy · 01.10.2026 · 58 (10) · 1084-1090
DOI: 10.1055/a-2891-4165 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Endoscopy, erschienen am 01.10.2026. Verfasst von Nitin Jagtap und 8 weiteren Autor:innen. Beteiligte Einrichtung: Asian Institute of Gastroenterology, Department of Medical Gastroenterology, India, Hyderabad. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Gastroplasty, Obesity, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Endoscopic sleeve gastroplasty (ESG) and semaglutide are established therapies for obesity. However, comparative real-world data remain limited. We compared the effectiveness and safety of ESG versus oral semaglutide 14 mg in adults with obesity. In a real-world retrospective comparative cohort study between January 2024 and April 2025, adults aged 18–65 years with body mass index (BMI) ≥30, or ≥27 kg/m2 with obesity-related comorbidity, treated with either ESG or oral semaglutide 14mg daily, and having 6-months’ follow-up were included. Primary endpoint was percentage total body weight loss (%TBWL) at 6 months. Secondary outcomes included treatment responder rates, adverse events, and 12-month weight outcomes. Analyses included Welch’s two-sample t-tests, analysis of covariance adjusted for age, sex, baseline BMI, and diabetes, inverse probability of treatment weighting (IPTW), and 1:1 propensity score matching. 150 patients were included (ESG n=50; semaglutide n=100). Baseline characteristics were broadly similar between groups. At 6 months, mean %TBWL was significantly higher with ESG than semaglutide (12.72±5.67% vs 8.67±3.84%, P=0.0001) that remained after covariate adjustment (adjusted mean difference 4.04%, P=0.0001), IPTW analysis (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Asian Institute of Gastroenterology, Department of Medical Gastroenterology, India, Hyderabad.
ORCID-Profile: Nitin Jagtap, Anudeep Katrevula, Shujaath Asif, Hardik Rughwani, Krithi Krishna Koduri
Zitieren
APA
Jagtap, N., Golchha, A., Katrevula, A., Asif, S., Rughwani, H., Koduri, K. K., Balenki, P., Kalapala, R., & Reddy, D. N. (2026). Endoscopic sleeve gastroplasty versus oral semaglutide for obesity: a real-world comparative cohort study. Endoscopy, 58(10), 1084-1090. https://doi.org/10.1055/a-2891-4165
Vancouver
Jagtap N, Golchha A, Katrevula A, Asif S, Rughwani H, Koduri KK, et al. Endoscopic sleeve gastroplasty versus oral semaglutide for obesity: a real-world comparative cohort study. Endoscopy. 2026;58(10):1084-1090. doi:10.1055/a-2891-4165
BibTeX
@article{Jagtap2026,
author = {Jagtap, Nitin and Golchha, Aman and Katrevula, Anudeep and Asif, Shujaath and Rughwani, Hardik and Koduri, Krithi Krishna and Balenki, Priyanka and Kalapala, Rakesh and Reddy, D Nageshwar},
title = {Endoscopic sleeve gastroplasty versus oral semaglutide for obesity: a real-world comparative cohort study},
journal = {Endoscopy},
year = {2026},
volume = {58},
number = {10},
pages = {1084--1090},
doi = {10.1055/a-2891-4165}
}
EUVIMED